Izgi Bayraktar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Izgi Bayraktar has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Nadir Yalçın
Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University
6 shared publications - Kutay Demirkan
Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Türkiye
4 shared publications - Aygin Bayraktar-Ekincioglu
Faculty of Pharmacy, Department of Clinical Pharmacy, Hacettepe University, Ankara, Turkey
2 shared publications - Emre Kara
Hacettepe University
2 shared publications Arzu Topeli
Department of Internal Medicine, Division of Intensive Care Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey
1 shared publication- Asli Akyol
Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Türkiye
1 shared publication
Latest Publications
- 1 September 2026
- Published by Hacettepe University in Hacettepe University Journal of the Faculty of Pharmacy
- Vol. 46 (3) , 241-249
A Simple and Reproducible Melatonin Syrup Formulation for Personalized Pediatric Therapies
Sleep disorders in children can negatively impact their development and quality of life. While melatonin is commonly used to manage these issues, there are no FDA-approved formulations specifically designed for children, and traditional tablet forms can be challenging for these patients. This study aims to develop a patient-friendly melatonin syrup formulation suitable for personalized pediatric therapies. Each teaspoon contains 1.0 mg of melatonin, allowing for flexible and precise dosing customized to individual patient needs. Melatonin content was quantified using a reversed-phase HPLC method with UV/Visible detector (HPLC-UV/Vis) ifadesi ‘with UV/Visible detector (HPLC-UV/Vis) that was developed and validated in line with ICH Q2(R1), demonstrating selectivity, linearity (1.0–30.0 μg/mL; R²=0.999), and intra- and inter-day accuracy and precision within 2%. Stability studies demonstrated that the syrup remains stable and retains its potency for at least seven days at room temperature. This syrup formulation enhances palatability and ease of administration, potentially improving therapeutic outcomes in children with sleep disorders through personalized treatment approaches. The syrup can be easily prepared using commercially available melatonin tablets in hospital pharmacies or home settings, using safe pediatric excipients.
- 1 September 2026
- Published by Hacettepe University in Hacettepe University Journal of the Faculty of Pharmacy
- Vol. 46 (3) , 241-249
A Simple and Reproducible Melatonin Syrup Formulation for Personalized Pediatric Therapies
Sleep disorders in children can negatively impact their development and quality of life. While melatonin is commonly used to manage these issues, there are no FDA-approved formulations specifically designed for children, and traditional tablet forms can be challenging for these patients. This study aims to develop a patient-friendly melatonin syrup formulation suitable for personalized pediatric therapies. Each teaspoon contains 1.0 mg of melatonin, allowing for flexible and precise dosing customized to individual patient needs. Melatonin content was quantified using a reversed-phase HPLC method with UV/Visible detector (HPLC-UV/Vis) ifadesi ‘with UV/Visible detector (HPLC-UV/Vis) that was developed and validated in line with ICH Q2(R1), demonstrating selectivity, linearity (1.0–30.0 μg/mL; R²=0.999), and intra- and inter-day accuracy and precision within 2%. Stability studies demonstrated that the syrup remains stable and retains its potency for at least seven days at room temperature. This syrup formulation enhances palatability and ease of administration, potentially improving therapeutic outcomes in children with sleep disorders through personalized treatment approaches. The syrup can be easily prepared using commercially available melatonin tablets in hospital pharmacies or home settings, using safe pediatric excipients.
- 16 March 2026
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 188, 107838
Beyond dose: Antipsychotic risk categories and sex-specific vulnerability to hyperprolactinemia in real-world longitudinal care
- 16 March 2026
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 188, 107838
Beyond dose: Antipsychotic risk categories and sex-specific vulnerability to hyperprolactinemia in real-world longitudinal care
- 9 February 2026
- Published by Oxford University Press (OUP) in International Journal of Pharmacy Practice
- Vol. 34 (5) , 714-715
ECHO+ model: enhancing pharmaceutical care with integrated ecological outcomes
- 9 February 2026
- Published by Oxford University Press (OUP) in International Journal of Pharmacy Practice
- Vol. 34 (5) , 714-715
ECHO+ model: enhancing pharmaceutical care with integrated ecological outcomes
- 30 January 2025
- Published by SAGE Publications in Clinical Child Psychology and Psychiatry
- Vol. 30 (2) , 516-528
Medication adherence and attitudes in adolescent psychiatry: Key influences
Adolescents with mental illnesses often struggle with adhering to prescribed medication regimens. This study investigates how patient perceptions influence medication adherence among adolescents with psychiatric disorders. It also examines the role of patient characteristics and medication-related factors on adherence and attitudes. The Pediatric Medication Adherence Scale (PMAS)- 9 questions and the Pediatric Attitude toward Medication Scale (PAMS)- 18 questions, two reliable self-report scales designed for the adolescent population, were used to assess negative adherence behaviors and patients’ perceptions of medication. Statistical analysis examined correlations between adherence, attitudes, and patient characteristics. The scales were administered to 288 adolescents with psychiatric disorders, and a significant correlation was found between concern scores and attitudes toward medication (r = 0.886, p < .05). Patients receiving monotherapy demonstrated lower concern scores and more positive attitudes ( p < .05). Experiencing side effects was significantly linked to reduced medication adherence and more negative attitudes toward treatment. Patients with eating disorders demonstrated more negative attitudes, while those using antidepressant-antipsychotic combinations demonstrated more negative attitudes than those using stimulants. This study emphasizes the necessity of addressing critical factors that influence medication adherence and attitudes toward psychiatric medication among adolescents with psychiatric disorders. In particular, it highlights the importance of considering concern perception, managing side effects, and evaluating polypharmacy to optimize pharmacotherapy in this population.
- 30 January 2025
- Published by SAGE Publications in Clinical Child Psychology and Psychiatry
- Vol. 30 (2) , 516-528
Medication adherence and attitudes in adolescent psychiatry: Key influences
Adolescents with mental illnesses often struggle with adhering to prescribed medication regimens. This study investigates how patient perceptions influence medication adherence among adolescents with psychiatric disorders. It also examines the role of patient characteristics and medication-related factors on adherence and attitudes. The Pediatric Medication Adherence Scale (PMAS)- 9 questions and the Pediatric Attitude toward Medication Scale (PAMS)- 18 questions, two reliable self-report scales designed for the adolescent population, were used to assess negative adherence behaviors and patients’ perceptions of medication. Statistical analysis examined correlations between adherence, attitudes, and patient characteristics. The scales were administered to 288 adolescents with psychiatric disorders, and a significant correlation was found between concern scores and attitudes toward medication (r = 0.886, p < .05). Patients receiving monotherapy demonstrated lower concern scores and more positive attitudes ( p < .05). Experiencing side effects was significantly linked to reduced medication adherence and more negative attitudes toward treatment. Patients with eating disorders demonstrated more negative attitudes, while those using antidepressant-antipsychotic combinations demonstrated more negative attitudes than those using stimulants. This study emphasizes the necessity of addressing critical factors that influence medication adherence and attitudes toward psychiatric medication among adolescents with psychiatric disorders. In particular, it highlights the importance of considering concern perception, managing side effects, and evaluating polypharmacy to optimize pharmacotherapy in this population.
- 19 December 2024
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 45 (1) , 1-16
Optimizing Individualized Antimicrobial Dosing in Pediatric Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background Therapeutic drug monitoring (TDM) and target concentration intervention (TCI) represent significant advancements in individualized medicine, aiming to tailor dosages based on patient-specific characteristics. These approaches account for intra- and inter-individual physiological and clinical variability, with the goal of improving target attainment and clinical remission while reducing treatment failure and adverse effects. Objectives The objective is to assess and enhance the current body of randomized controlled trials (RCTs) that have investigated alternative personalized dosing strategies, such as TDM and TCI, in terms of their efficacy and safety for individualized antimicrobial dosing in pediatric populations. Only studies that compared different dosing regimens and reported plasma concentrations were included in the analysis. Methods Databases such as MEDLINE, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials were searched until January 3rd, 2024. Only published, peer-reviewed RCTs were considered for inclusion. The study focused on human subjects aged < 18 years who were receiving an antimicrobial drug. The interventions compared experimental dosing versus standard dosing with TDM or TCI. The risk of bias was assessed using version 2 of the Cochrane risk-of-bias tool for randomized trials. The primary outcome was the attainment of target concentrations, while secondary outcomes included adverse effects, clinical remission, and treatment failure. Data synthesis was performed using the restricted maximum likelihood method, and the risk ratio (RR) was used as the measure of effect size. Results Only 11 TDM-based RCTs were included in the study [experimental vs standard doses: 592 (51.3%) patients vs 563 (48.7%) patients]. Experimental dose was significantly associated with improvement in target attainment (RR 1.2587, OR 1.0717–1.4786; p = 0.0051). However, experimental antimicrobial dose optimization was non-significantly associated with a numerical decrease in treatment failure (RR 0.8966, OR 0.7749–1.0374; p = 0.1424). In addition, it was not significant associated with higher adverse effects [RR 1.3408, odds ratio (OR) 0.1783–10.0825; p = 0.7757] and clinical remission rates (RR 4.0589, OR 0.2494–66.0558; p = 0.3250). Conclusions This meta-analysis showed that only target attainment using TDM was significantly improved in pediatric patients treated with experimental doses of antimicrobials compared to standard doses. Larger TCI-focused RCTs are needed to significantly improve treatment failure, adverse effects, and clinical remission.
- 19 December 2024
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 45 (1) , 1-16
Optimizing Individualized Antimicrobial Dosing in Pediatric Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background Therapeutic drug monitoring (TDM) and target concentration intervention (TCI) represent significant advancements in individualized medicine, aiming to tailor dosages based on patient-specific characteristics. These approaches account for intra- and inter-individual physiological and clinical variability, with the goal of improving target attainment and clinical remission while reducing treatment failure and adverse effects. Objectives The objective is to assess and enhance the current body of randomized controlled trials (RCTs) that have investigated alternative personalized dosing strategies, such as TDM and TCI, in terms of their efficacy and safety for individualized antimicrobial dosing in pediatric populations. Only studies that compared different dosing regimens and reported plasma concentrations were included in the analysis. Methods Databases such as MEDLINE, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials were searched until January 3rd, 2024. Only published, peer-reviewed RCTs were considered for inclusion. The study focused on human subjects aged < 18 years who were receiving an antimicrobial drug. The interventions compared experimental dosing versus standard dosing with TDM or TCI. The risk of bias was assessed using version 2 of the Cochrane risk-of-bias tool for randomized trials. The primary outcome was the attainment of target concentrations, while secondary outcomes included adverse effects, clinical remission, and treatment failure. Data synthesis was performed using the restricted maximum likelihood method, and the risk ratio (RR) was used as the measure of effect size. Results Only 11 TDM-based RCTs were included in the study [experimental vs standard doses: 592 (51.3%) patients vs 563 (48.7%) patients]. Experimental dose was significantly associated with improvement in target attainment (RR 1.2587, OR 1.0717–1.4786; p = 0.0051). However, experimental antimicrobial dose optimization was non-significantly associated with a numerical decrease in treatment failure (RR 0.8966, OR 0.7749–1.0374; p = 0.1424). In addition, it was not significant associated with higher adverse effects [RR 1.3408, odds ratio (OR) 0.1783–10.0825; p = 0.7757] and clinical remission rates (RR 4.0589, OR 0.2494–66.0558; p = 0.3250). Conclusions This meta-analysis showed that only target attainment using TDM was significantly improved in pediatric patients treated with experimental doses of antimicrobials compared to standard doses. Larger TCI-focused RCTs are needed to significantly improve treatment failure, adverse effects, and clinical remission.
- 12 September 2024
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 29 (3) , 398-402
Cefepime Related Neurological Complications in a Dialysis Patient: A Case Report
- 12 September 2024
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 29 (3) , 398-402
Cefepime Related Neurological Complications in a Dialysis Patient: A Case Report
- 27 July 2024
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 33 (12) , 4393-4403
Advancing patient care: novel scales for assessing adherence and attitudes toward medication among adolescents with psychiatric disorders and their parents
Adolescents with psychiatric disorders may struggle with medication adherence and this can lead to ineffective treatment. Subjective factors, such as attitudes, beliefs, experiences, have a greater impact on adherence in adolescents than objective factors. To better understand these subjective attitudes, self-evaluation rating scales should be developed. The study aimed to develop two scales - Pediatric Medication Adherence Scale (PMAS) and Pediatric Attitudes toward Medication Scale (PAMS) - to assess adherence and attitudes toward medication for pediatric patients and their parents. Total of 288 pediatric patients (67% female) between the ages of 12–18 (mean [standard deviation] age of 15.25 [1.59] years) with psychiatric disorders and 255 parents (83.53% mothers) were administered the scales. The validity of the scales was evaluated through the content validity index and explanatory factor analyses. To evaluate reliability, Cronbach’s alpha, and test-retest methods were utilized. The validity and reliability of the PMAS (9 questions for patients, 6 questions for parents) and PAMS (18 questions for patients, 20 questions for parents), Cronbach’s alpha values and intraclass correlation coefficients were found above 0.7 for each scale and showed well establishment for this particular population. Analysis revealed that anxiety scores had a greater impact on total attitude scores than necessity scores (p < 0.05). Parent and patient adherence scores were similar, and negative parental attitudes toward medication were associated with lower patient adherence. The present study represents a novel attempt to design a medication adherence and attitude questionnaire for adolescents with psychiatric disorders, along with a parental version.
- 27 July 2024
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 33 (12) , 4393-4403
Advancing patient care: novel scales for assessing adherence and attitudes toward medication among adolescents with psychiatric disorders and their parents
Adolescents with psychiatric disorders may struggle with medication adherence and this can lead to ineffective treatment. Subjective factors, such as attitudes, beliefs, experiences, have a greater impact on adherence in adolescents than objective factors. To better understand these subjective attitudes, self-evaluation rating scales should be developed. The study aimed to develop two scales - Pediatric Medication Adherence Scale (PMAS) and Pediatric Attitudes toward Medication Scale (PAMS) - to assess adherence and attitudes toward medication for pediatric patients and their parents. Total of 288 pediatric patients (67% female) between the ages of 12–18 (mean [standard deviation] age of 15.25 [1.59] years) with psychiatric disorders and 255 parents (83.53% mothers) were administered the scales. The validity of the scales was evaluated through the content validity index and explanatory factor analyses. To evaluate reliability, Cronbach’s alpha, and test-retest methods were utilized. The validity and reliability of the PMAS (9 questions for patients, 6 questions for parents) and PAMS (18 questions for patients, 20 questions for parents), Cronbach’s alpha values and intraclass correlation coefficients were found above 0.7 for each scale and showed well establishment for this particular population. Analysis revealed that anxiety scores had a greater impact on total attitude scores than necessity scores (p < 0.05). Parent and patient adherence scores were similar, and negative parental attitudes toward medication were associated with lower patient adherence. The present study represents a novel attempt to design a medication adherence and attitude questionnaire for adolescents with psychiatric disorders, along with a parental version.
- 24 July 2024
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 32 (5) , 491.1-492
Beyond conventional dosing: tailoring antimicrobial regimens for cachexia
- 24 July 2024
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 32 (5) , 491.1-492
Beyond conventional dosing: tailoring antimicrobial regimens for cachexia
- 7 June 2023
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 31 (1) , 66-67
Polymyxin B-related neurotoxicity: a brief case report
Polymyxin B and colistin are considered the last therapeutic option to treat infections caused by highly drug-resistant bacteria. However, their administration may lead to various adverse effects such as nephrotoxicity, neurotoxicity, and allergic reactions. The current case report presents the clinical manifestation of polymyxin B-associated neurotoxicity in a female patient with no chronic illness history. The patient was rescued from under rubble during an earthquake. She was diagnosed with an intra-abdominal infection caused by Acinetobacter baumannii (A. baumannii). After the initiation of the polymyxin B infusion, the patient developed numbness and tingling sensations in her hands, face, and head. On discontinuing polymyxin B and starting colistimethate, the patient’s symptoms improved. Therefore, healthcare professionals should be aware of the potential risk factors associated with neurotoxicity in patients receiving polymyxin B. On identifying such symptoms treatment should be discontinued promptly to prevent further neurological damage.
- 7 June 2023
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 31 (1) , 66-67
Polymyxin B-related neurotoxicity: a brief case report
Polymyxin B and colistin are considered the last therapeutic option to treat infections caused by highly drug-resistant bacteria. However, their administration may lead to various adverse effects such as nephrotoxicity, neurotoxicity, and allergic reactions. The current case report presents the clinical manifestation of polymyxin B-associated neurotoxicity in a female patient with no chronic illness history. The patient was rescued from under rubble during an earthquake. She was diagnosed with an intra-abdominal infection caused by Acinetobacter baumannii (A. baumannii). After the initiation of the polymyxin B infusion, the patient developed numbness and tingling sensations in her hands, face, and head. On discontinuing polymyxin B and starting colistimethate, the patient’s symptoms improved. Therefore, healthcare professionals should be aware of the potential risk factors associated with neurotoxicity in patients receiving polymyxin B. On identifying such symptoms treatment should be discontinued promptly to prevent further neurological damage.